Dyax’s BLA For Acute Hereditary Angioedema Goes Before FDA Advisory Panel In February
This article was originally published in The Pink Sheet Daily
Executive Summary
DX-88 could be one step closer to becoming the first treatment approved for acute attacks of HAE; Pulmonary-Allergy Drugs Advisory Committee review is Feb. 4.
You may also be interested in...
Cinryze Prophylaxis Approval Leaves Window For HAE Treatment Contenders
The approval of ViroPharma/Lev's hereditary angioedema therapyCinryze on Oct. 10, with orphan status for prophylaxis only, leaves the window open for other C1 esterase inhibitors to claim the prize of orphan exclusivity for treatment of acute attacks. But ViroPharma thinks it can win that too
Dyax Completes Rolling BLA For HAE Candidate DX-88
Company seeks priority review, which if granted could set an FDA action date in March.
Dyax’s HAE Candidate Meets Clinical Endpoints In Phase III Trial
With the completion of Phase III testing, Dyax plans to submit final piece of rolling BLA for DX-88 in early fourth quarter.